Trial Identifiers
Use the hyperlinks, where available to access additional clinical trial information.
Scientific Title
A Randomized, Multicenter, Double Blind, Phase III Study of Adjuvant Nivolumab or Placebo in Subjects With Resected Esophageal, or Gastroesophageal Junction Cancer
Commercial Sponsor
Bristol-Myers Squibb (BMS)
Summary
The purpose of this study is to determine whether nivolumab will improve overall survival, disease-free survival, or both compared with placebo.